TKNO ALPHA TEKNOVA INC

Teknova to Participate in Upcoming Investor Conferences

Teknova to Participate in Upcoming Investor Conferences

HOLLISTER, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, research, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conferences:

Stephens Annual Investment Conference

November 15 - 17, 2022

Nashville, TN

Fireside Chat: 1:00 p.m. CT, Thursday, November 17, 2022

Piper Sandler 34th Annual Healthcare Conference

November 29 - December 1, 2022

New York, NY

Company Presentation: 12:50 p.m. ET, Wednesday, November 30, 2022

Stephen Gunstream, Teknova’s President and Chief Executive Officer, and Matt Lowell, Teknova’s Chief Financial Officer, plan to discuss Company highlights, their product portfolio, market trends, key growth drivers, and long-term market opportunities.

Live audio webcasts for each conference may be accessed from the Investor Relations section of the Company’s website: /. The webcasts will be available on the Company’s website for approximately 90 days after each event.

About Teknova

Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.

Investor Contacts

Matt Lowell

Chief Financial Officer



Sara Michelmore

MacDougall Advisors



Media Contact

Jenn Henry

Senior Vice President, Marketing



EN
03/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALPHA TEKNOVA INC

 PRESS RELEASE

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results ...

Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market. Teknova will host a webcast and conference call on Thursday...

 PRESS RELEASE

Teknova Reports Third Quarter 2025 Financial Results

Teknova Reports Third Quarter 2025 Financial Results Third quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30...

 PRESS RELEASE

Teknova to Report Third Quarter 2025 Financial Results on November 6, ...

Teknova to Report Third Quarter 2025 Financial Results on November 6, 2025 HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, November 6, 2025, beginning a...

 PRESS RELEASE

Teknova Reports Second Quarter 2025 Financial Results

Teknova Reports Second Quarter 2025 Financial Results Second quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, ...

 PRESS RELEASE

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2...

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025 HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, August 7, 2025, beginning at 5 p.m. ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch